Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Health Economics & Reimbursement

MDMA for Health Economics & Reimbursement

6 papers and 1 clinical trial exploring mdma as a treatment for health economics & reimbursement.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationApproximately 300 million individuals worldwide suffer from depression, with PTSD affecting about 7-8% of the US population at some point in their lives.

Health Economics & Reimbursement

Psychedelic-assisted therapies are gaining traction in the health economics domain, with promising findings regarding their efficacy in treating mental health disorders. As the FDA considers approval for compounds like MDMA and psilocybin, the economic implications, including reimbursement models, are increasingly relevant to healthcare systems worldwide.

Full Health Economics & Reimbursement profile

Academic Research

6 papers
Open Accessindividual

The Potential Economic and Public Health Impact of MDMA-Assisted Group Therapy for PTSD in Ukraine

Using a decision-analysis model for 1,000 Ukrainian PTSD patients, the study estimates MDMA-assisted group therapy with supplemental individual sessions would cost US$1.1m, avert 19.2 deaths, gain 717 QALYs, have an ICER of US$1,537/QALY and produce net societal savings of US$2.6m, with scaled 50% coverage over 10 years potentially saving ~48,000 lives, 1.5 million QALYs and US$5.6bn. These results indicate MAT is likely to be cost‑effective or cost‑saving and could substantially improve population health, supporting its inclusion in Ukraine’s PTSD treatment strategy.

Published
August 21, 2025
Journal
World Medical & Health Policy
Authors
Marseille, E., Chernoloz, O., Orlov, |. O.
Open Accessindividual

Cost-effectiveness of midomafetamine-assisted therapy (MDMA-AT) in chronic and treatment-resistant post-traumatic stress disorder of moderate or higher severity: A health-economic model

Using a health state-transition model, midomafetamine-assisted therapy for chronic, moderate-or-higher PTSD produced a 0.377 QALY gain over five years at an incremental cost of $31,613, yielding an ICER of $83,845 per QALY. These results indicate MDMA-AT is likely cost-effective versus placebo with therapy at a $150,000 willingness-to-pay threshold (assuming a $12,000 per-session drug price).

Published
November 12, 2024
Journal
PLOS ONE
Authors
Stanghellini, G.
Open Accessindividual

MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians

This focus group study (n=19) investigated the perspectives of adolescents, parents, and clinicians on MDMA-assisted psychotherapy for adolescents with PTSD. Initial attitudes towards MDMA were mainly unfavourable, but after an explanation of the therapy, all but one participant supported its potential use, emphasizing the importance of research.

Published
September 1, 2023
Journal
Drug Science Policy and Law
Authors
Van Vugt, A. S., Zijlmans, J., Lindauer, R., Van Dam, L.
Open Accessmeta

The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study

This study (2022) uses a decision-analytic model to assess the cost and health benefits of expanded access to MDMA-assisted therapy (MDMA-AT) in the phase III clinical trials from MAPS. Expanding access to MDMA-AT to 25-75% of eligible patients was projected to avert 43,618-106,932 deaths and gain 3.3-8.2 million quality-adjusted life-years (QALYs).

Published
March 4, 2022
Journal
Clinical Drug Investigation
Authors
Avancena, A. L. V., Kahn, J. G., Marseille, E.
Open Accessindividual

Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial

Using phase 3 trial data and a Markov model, MDMA-assisted therapy for severe or extreme chronic PTSD costs US$11,537 per patient and is cost-saving from a US payer perspective—producing discounted net health‑care savings of US$132.9 million per 1,000 patients, accruing 4,856 QALYs and averting 61.4 premature deaths over 30 years with a 3.8‑year payback. The more intensive three‑session phase 3 regimen yields greater medical savings and health benefits than shorter two‑session regimens.

Published
February 25, 2022
Journal
PLOS ONE
Authors
Marseille, E., Mitchell, M. J., Khan, J. G.
Open Accessmeta

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

This study (2020) on the costs (and benefits) of MDMA-assisted therapy for PTSD finds it to be more cost-effective than other treatments. It's based on the data from six double-blind, placebo-controlled phase II trials (n=105) done by MAPS.

Published
October 14, 2020
Journal
PLOS ONE
Authors
Marseille, E., Kahn, J. G., Yazar-Klosinski, B., Doblin, R.

Clinical Trials

1 trial
RecruitingPhase II

MDMA-assisted Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

This randomized, interventional trial (n=30) will compare MDMA-assisted Cognitive Processing Therapy (three MDMA sessions plus preparatory and integration therapy) versus standard Cognitive Processing Therapy for Veterans with severe PTSD.

Started
September 1, 2023
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT05837845

Explore further

Search all MDMA papers Search all Health Economics & Reimbursement trials Full MDMA profile Full Health Economics & Reimbursement profile